thalidomide has been researched along with Purpura, Thrombocytopenic, Idiopathic in 5 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Purpura, Thrombocytopenic, Idiopathic: Thrombocytopenia occurring in the absence of toxic exposure or a disease associated with decreased platelets. It is mediated by immune mechanisms, in most cases IMMUNOGLOBULIN G autoantibodies which attach to platelets and subsequently undergo destruction by macrophages. The disease is seen in acute (affecting children) and chronic (adult) forms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A patient with refractory primary immune thrombocytopenia (ITP) characterised by severe skin and mucosal bleedings was treated with several ITP-directed therapies including cyclophosphamide." | 1.46 | Refractory primary immune thrombocytopenia with subsequent del(5q) MDS: complete remission of both after lenalidomide. ( Frederiksen, H; Marcher, CW; Mortensen, TB; Preiss, B, 2017) |
| "Thalidomide (THD) is an immunomodulatory agent used to treat immune-mediated diseases." | 1.39 | Thalidomide corrects impaired mesenchymal stem cell function in inducing tolerogenic DCs in patients with immune thrombocytopenia. ( Guo, CS; He, WD; Hou, M; Hou, XY; Hou, Y; Li, H; Liu, XG; Ma, J; Min, YN; Ning, YN; Peng, J; Qin, P; Shao, LL; Shi, Y; Wang, N; Xu, M; Yu, YY; Zhou, H, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, ZG | 1 |
| Wen, RT | 1 |
| Zhang, YM | 1 |
| Wu, GC | 1 |
| Chen, WJ | 1 |
| Wang, YF | 1 |
| Weng, ZY | 1 |
| Wen, SS | 1 |
| Zhang, XJ | 1 |
| Guan, MH | 1 |
| Ma, J | 1 |
| Ning, YN | 1 |
| Xu, M | 1 |
| Hou, Y | 1 |
| Wang, N | 1 |
| Hou, XY | 1 |
| Yu, YY | 1 |
| Li, H | 1 |
| He, WD | 1 |
| Shao, LL | 1 |
| Zhou, H | 1 |
| Min, YN | 1 |
| Liu, XG | 1 |
| Shi, Y | 1 |
| Qin, P | 1 |
| Guo, CS | 1 |
| Hou, M | 1 |
| Peng, J | 1 |
| Yin, Y | 1 |
| Deng, M | 1 |
| Peng, H | 1 |
| Zhang, G | 1 |
| Mortensen, TB | 1 |
| Frederiksen, H | 1 |
| Marcher, CW | 1 |
| Preiss, B | 1 |
| Falco, P | 1 |
| Bertola, A | 1 |
| Bringhen, S | 1 |
| Cavallo, F | 1 |
| Boccadoro, M | 1 |
| Palumbo, A | 1 |
1 trial available for thalidomide and Purpura, Thrombocytopenic, Idiopathic
| Article | Year |
|---|---|
Thalidomide induce response in patients with corticosteroid-resistant or relapsed ITP by upregulating Neuropilin-1 expression.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; B-Lymphocytes, Regulatory; Drug Resistance; Female; Huma | 2019 |
4 other studies available for thalidomide and Purpura, Thrombocytopenic, Idiopathic
| Article | Year |
|---|---|
Thalidomide corrects impaired mesenchymal stem cell function in inducing tolerogenic DCs in patients with immune thrombocytopenia.
Topics: Adolescent; Adult; Aged; Case-Control Studies; Cell Proliferation; Dendritic Cells; Early Growth Res | 2013 |
Effects of low-dose thalidomide in chronic refractory immune thrombocytopenia and contributions to the dispensation of glucocorticoid dependence.
Topics: Adult; Chronic Disease; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Male; Middle Aged | 2016 |
Refractory primary immune thrombocytopenia with subsequent del(5q) MDS: complete remission of both after lenalidomide.
Topics: Chromosome Deletion; Chromosomes, Human, Pair 5; Drug Resistance; Humans; Immunologic Factors; Lenal | 2017 |
Successful management of immune thrombocytopenic purpura with thalidomide in a patient with multiple myeloma.
Topics: Antineoplastic Agents; Combined Modality Therapy; Drug Resistance; Humans; Immunoglobulins, Intraven | 2004 |